Table 4.
Current COVID-19 vaccines under use and in pipeline.
| Vaccine Name | Manufacturer | Vaccine basis | Vaccine approval |
|---|---|---|---|
| Comirnaty (also known as tozinameran or BNT162b2) |
Pfizer-BioNTech | mRNA |
Approved in U.S |
| mRNA-1273 or Spikevax | Moderna | mRNA | Approved in Switzerland. |
| ZyCoV-D | Zydus | DNA | Emergency use in India |
| Sputnik V (also known as Gam-Covid-Vac) |
Gamaleya Research Institute | Ad5 and Ad26 | Emergency use in Russia |
| Vaxzevria (also known as AZD1222, or Covishield in India) |
University of Oxford-AstraZeneca | ChAdOx1 | Approved for use in Brazil. Emergency use in other countries |
| Convidecia (also known as Ad5-nCoV) |
CanSino Biologics- Academy of Military Medical Sciences. |
Ad5 | Approved for use in China |
| Ad26.COV2.S | Johnson & Johnson | Ad26 | Emergency use in Andorra, Australia, Bahamas, other countries |
| EpiVacCorona, Aurora-CoV | Vector Institute | peptides | Approved for use in Turkmenistan. |
| ZF2001, Zifivax | Anhui Zhifei Longcom-Institute of Medical Biology at the Chinese Academy of Medical Sciences | Adjuvant-RBD | Emergency use in China, Uzbekistan. |
| Soberana 2, or PastoCoVac (in Iran) | Finlay Vaccine Institute | spike protein fused to a standard tetanus vaccine | Emergency use in Cuba, Iran, Nicaragua |
| Abdala | Center for Genetic Engineering and Biotechnology of Cuba | RBD | Emergency use in Cuba, Nicaragua, Venezuela, Vietnam. |
| BBIBP-CorV | Beijing Institute of Biological Products-Sinopharm | inactivated | Approved for use in Bahrain, China, United Arab Emirates. |
| CoronaVac (formerly PiCoVacc) | Sinovac | Inactivated | Approved for use in China. |
| Wuhan Vaccine | Sinopharm-Wuhan | Inactivated | Approved for use in China. |
| Covaxin (also known as BBV152 A, B, C) | Bharat Biotech- Indian Council of Medical Research-National Institute of Virology |
inactivated | Emergecy use in India |
| QazVac | Research Institute for Biological Safety Problems | inactivated | Early use in Kazakhstan, Kyrgyzstan |
| COVIran Barekat | Shafa Pharmed Pars | inactivated | Emergency use in Iran. |
| CoviVac | Chumakov Center | inactivated | Early use in Russia. |
| Vaccines in pipeline | |||
| AG0302-COVID19 | AnGes-Osaka University-Takara Bio | DNA | |
| HGC019 | Gennova Biopharmaceuticals-HDT Bio | self-amplifying RNA | |
| COVID-eVax | Takis Biotech-Rottapharm Biotech, | DNA | |
| DS-5670 | Daiichi Sankyo-University of Tokyo | mRNA | |
| EXG-5003 | Elixirgen Therapeutics | RNA | |
| EG-COVID | Eyegene | mRNA | |
| ChulaCov19 | Chulalongkorn University | mRNA | |
| Covigenix VAX-001 | Entos Pharmaceuticals | DNA | |
| CORVax12 | OncoSec Immunotherapies | loop of DNA that encodes both the spike protein and IL-12 | |
| COVIGEN | BioNet-Asia-Technovalia | DNA | |
| SCOV1, SCOV2 | Scancell | DNA | |
| AdCLD-CoV19 | Cellid | Ad5 and Ad35 | |
| BCD-250 | BIOCAD | adenovirus-associated virus AAV-5 | |
| – | ImmunityBio | Ad5 | |
| Meissa Vaccines | RSV | ||
| CVXGA1 | University of Georgia-University of Iowa | canine parainfluenza virus | |
| COVID-19-EDV | EnGeneIC | ||
| Soberana 1 | Finlay Vaccine Institute | RBD | |
| EuCorVac-19 | EuBiologics | protein | |
| VBI-2902a | VBI Vaccines | virus-like protein shells | |
| AKS-452 | Akston Biosciences | RBD | |
| IVX-411 | Icosavax-Seqirus | RBD | |
| QazCoVac-P | Research Institute for Biological Safety Problems | protein | |
| St. Petersburg Scientific Research Institute of Vaccines and Sera | protein subunit | ||
| Mambisa | Center for Genetic Engineering and Biotechnology of Cuba | RBD | |
Source: The New York Times.